Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05101109 |
|---|---|
| Brief Title: | Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors |
| First Submitted : | October 6, 2021 |
| First Submitted that Met QC Criteria : | October 19, 2021 |
| First Posted : | November 1, 2021 |
| Last Update Submitted that Met QC Criteria : | January 29, 2024 |
| Last Update Posted : | January 31, 2024 |